DrugPatentWatch Database Preview
Drugs in Development Information for Clazakizumab
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug Clazakizumab?
Clazakizumab is an investigational drug.
There have been 4 clinical trials for Clazakizumab.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2019.
The most common disease conditions in clinical trials are Asthma, Arthritis, Rheumatoid, and Arthritis. The leading clinical trial sponsors are Vitaeris INC, ICON Clinical Research, and Medical University of Vienna.
There are three US patents protecting this investigational drug and twenty-five international patents.
Summary for Clazakizumab
| US Patents | 3 |
| International Patents | 25 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-03-01) |
| Vendors | 0 |
Recent Clinical Trials for Clazakizumab
| Title | Sponsor | Phase |
|---|---|---|
| PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study | University of North Carolina, Chapel Hill | Phase 2 |
| Interleukin 6 Blockade Modifying Antibody-Mediated Graft Injury and Estimated Glomerular Filtration Rate (eGFR) Decline | ICON Clinical Research | Phase 3 |
Clinical Trial Summary for Clazakizumab
Top disease conditions for Clazakizumab
Top clinical trial sponsors for Clazakizumab
US Patents for Clazakizumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Clazakizumab | Start Trial | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | Start Trial |
| Clazakizumab | Start Trial | Cholestosome vesicles for incorporation of molecules into chylomicrons | THERASYN SENSORS, INC. (Eggertsville, NY) | Start Trial |
| Clazakizumab | Start Trial | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Clazakizumab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Clazakizumab | Argentina | 108097 | 2036-04-04 | Start Trial |
| Clazakizumab | Australia | 2017246228 | 2036-04-04 | Start Trial |
| Clazakizumab | Brazil | 112018070214 | 2036-04-04 | Start Trial |
| Clazakizumab | Canada | 3019137 | 2036-04-04 | Start Trial |
| Clazakizumab | Chile | 2018002803 | 2036-04-04 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
